Our Science
OUR SCIENCE
Congress Presentations
This section includes posters and presentations related to Arvinas’ PROTAC science, discovery compounds, and clinical-stage assets presented at scientific congresses in the past three years.
AD/PD 2026 | Copenhagen, Denmark
Mar 17 - 21, 2026
Poster
Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ARV-102, a PROTAC LRRK2 Degrader, in Participants With Parkinson’s DiseaseSFN 2025 | San Diego, CA
Nov 15 - 19, 2025
Poster
ARV-102, a PROTAC LRRK2 Degrader, Modulates Pathways Associated With Parkinson’s Disease and Progressive Supranuclear Palsy: Proteomic Analyses of CSF From Non-human Primates and Healthy VolunteersWMS 2025 | Vienna, Austria
Oct 7 - 11, 2025
Poster
Oral ARV-027 Induces PolyQ-AR Degradation and Improves Muscle Strength and Endurance in a Murine Model of SBMAMDS 2025 | Honolulu, HI
Oct 5 - 9, 2025
Poster
First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ARV-102, a PROTAC LRRK2 Degrader, in Healthy ParticipantsMDS 2025 | Honolulu, HI
Oct 5 - 9, 2025
Poster
First Clinical Trials of ARV-102, a PROTAC LRRK2 Degrader: Characterization of Pathway Engagement in Healthy Volunteers and Patients With Parkinson’s DiseaseIAPRD 2025 | New York City, NY
May 7 - 10, 2025
Poster
First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of ARV-102, a PROTAC LRRK2 Degrader, in Healthy VolunteersAD/PD 2025 | Vienna, Austria
Apr 1 - 5, 2025
Presentation
First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of ARV-102, a PROTAC LRRK2 Degrader, in Healthy VolunteersBiennial International LRRK2 Meeting 2024 | Crete, Greece
Jun 18 - 21, 2024
Presentation
Development of Potent, Orally Bioavailable PROTAC® LRRK2 Degrader Molecules as Potential Disease Modifying Therapeutics for NeurodegenerationMDS 2023 | Copenhagen, Denmark
Aug 27 - 31, 2023